-
APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Adjuvant Chemotherapy in Patients with Resected Pancreatic Cancer and a Pathogenic BRCA1 BRCA2 or PALB2 Mutation
This phase II trial investigates how well the addition of olaparib following completion of surgery and chemotherapy works in treating patients with pancreatic cancer that ...Phase
Interventional
-
DAY101-001/PNOC026/FIREFLY-1: A Phase 2 Open-Label Multicenter Study to Evaluate the Safety and Efficacy of the Oral Pan-RAF Inhibitor DAY101 in Pediatric Patients with RAF-Altered Recurrent or Progressive Low-Grade Glioma and Advanced Solid Tumors
DAY101 is an oral, selective, small-molecule, Type II pan-RAF kinase inhibitor that is being developed by DOT Therapeutics-1 Inc. (Day One, the Sponsor) for the ...Phase
Interventional
-
Site for AALL1821: A Phase 2 Study of Blinatumomab (NSC# 765986 IND# 125462) in Combination with Nivolumab (NSC# 748726 IND# 125462) a Checkpoint Inhibitor of PD-1 in B-ALL Patients Aged >/=1 to
Site for This phase II trial investigates how well nivolumab when given together with blinatumomab work compared to blinatumomab alone in treating patients with CD19 ...Phase
Interventional
-
A randomized phase II trial of adjuvant trastuzumab emtansine (T-DM1) followed by subcutaneous trastuzumab versus paclitaxel in combination with subcutaneous trastuzumab for Stage I HER2-positive breast cancer (ATEMPT 2.0)
This is a randomized phase II adjuvant study for women and men with Stage I HER2-positive invasive breast cancer. At least 500 eligible patients will ...Phase
Interventional
-
Interventional randomized double-blind parallel-group placebo-controlled multi-centre study to assess the efficacy safety and tolerability of Lu AF82422 in patients with Multiple System Atrophy
This is a phase II, interventional, randomized, double-blind, parallel-group, placebocontrolled, multi-centre study of the efficacy (slowing disease progression), safety, and tolerability of Lu AF82422 in ...Phase
Interventional
-
A Follow-Up Open-Label Research Evaluation of Sustained Treatment with Aficamten (CK-3773274) in Hypertrophic Cardiomyopathy (HCM)
This is an open-label study of CK-3773274 in patients with HCM. The treatment duration is anticipated to be multiple years, concluding when marketing authorization is ...Phase
Interventional
-
CBYL719F12201: EPIK-P2 Phase II double-blind study w/ upfront 16-week randomized placebo-controlled period to assess efficacy safety & pharmacokinetics of alpelisib (BYL719) in pediatric & adult patients w/ PIK3CA-related overgrowth spectrum (PROS)
This study will be the first prospective study of alpelisib in participants with PROS. Local overgrowth or hemihypertrophy, mostly progressive, is the most frequently observed ...Phase
Interventional
-
Biomarker and Edema Attenuation in IntraCerebral hemorrhage (BEACH)
This first-in-patient phase 2a pilot study will assess the safety and tolerability of MW01-6-189WH (hereafter called MW189) in patients with Intracerebral Hemorrhage (ICH). This study ...Phase
Interventional
-
A Phase II Study of Ribociclib And Endocrine Treatment of Physician s Choice for Locoregional Recurrent Resected Hormone Receptor Positive HER2 Negative Breast Cancer (RaPhLRR Study)
Primary Objective: To estimate subsequent recurrence-free survival (RFS) at 3 years for ribociclib when administered with ET (AIs or fulvestrant), in patients with Hormone Receptor ...Phase
Interventional
-
Randomized placebo controlled trial to determine the biological signature of cannabidiol as a treatment for social anxiety disorder
The goals of these two phased studies (“R61” followed by “R33”) are to establish a biological signature of CBD’s putative therapeutic effects in SAD ...Phase
Interventional
